Physician profile
Halary H Patch
NPI 1255631248
$1,764.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $828 · 2023: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.15 | 2021-2023 | Farxiga, Breztri, Brilinta |
| Lilly USA, LLC | $238.12 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $152.45 | 2022-2023 | |
| Abbott Laboratories | $133.75 | 2023 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.16 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $115.44 | 2022-2023 | Rybelsus, Ozempic |
| Amgen INC. | $83.47 | 2021-2023 | Repatha |
| Merck Sharp & Dohme LLC | $74.10 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Medtronic, INC. | $53.11 | 2021-2022 | |
| Amarin Pharma, INC. | $39.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.24 | 2023 | Xarelto |
| Alfasigma USA, INC. | $21.04 | 2022 | |
| Corcept Therapeutics | $18.70 | 2022 | |
| Tandem Diabetes Care, INC. | $18.23 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $17.73 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halary Patch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.